Abstract Number: 2095 Presentation Title: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE)
Abstract Number: 559 Presentation Title: The molecular kinetics of p21 and Cdk4 dictates irreversible G0/G1 phase cell cycle arrest in CRPC cells
Abstract Number: 2433 Presentation Title: In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models
Abstract Number: 3388 Presentation Title: Novel aurora plus Bruton's tyrosine kinase-targeted therapies for aggressive B-cell non-Hodgkin's lymphoma
Are you sure these are 2013 presentations. You mention amuvatinib, which they stopped it in trials. T he info on AT13387 is old. I'm just wondering why AACR would allow abstracts to be viewable a month in advance?
I'll let you figure it out. Just happy we're over $4. I noticed the same posters that attacked me on my posts of the pipeline a few months ago, are now the same posters today on the bandwagon.
If you do have the right info, then look for Novartis trial of LEE011, they are to present data also at AACR.
I believe this is just publication of the data from the studies which led to ASTX discontinuing the development of Amuvantinib in September. There were some positive response but it did not achieve the response endpoint sufficient to justify further development. The firm has said it is willing to license the product if some other firm is interested in further testing/development.